Nefrogen systemisk fibrose ved bruk av MR-kontrastmiddel

Tidsskrift for den Norske Laegeforening

Volumn 129, Issue 3, 2009, Pages 180-182

  Christiansen, Rolf E F ^a   Sviland, Lisbet ^b   Sekse, Ingegjerd ^c   Svarstad, Einar ^c,d  

^a Medisinsk Avdeling   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d Universiteteti   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM PENTETATE;

ADULT; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; HUMAN; IMMUNOLOGY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; PATHOLOGY; REVIEW; SKIN;

ADULT; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEPHROGENIC FIBROSING DERMOPATHY; SKIN;

EID: 59649121595     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.09.33117     Document Type: Review

References (17)

1. Hallan SI, Coresh J, Astor BC. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 2275-84.
2. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: 16-23.
3. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-6.
4. Nortier JL, del Marmol V. Nephrogenic systemic fibrosis - the need for a multidisciplinary approach. Nephrol Dial Transplant 2007; 22: 3097-101.
5. Cowper SE, Robin HS, Steinberg SM et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1.
6. Ting WW, Stone MS, Madison KC et al. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903-6.
7. Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis - setting the record straight. Semin Arthritis Rheum 2006; 35: 208-10.
8. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 2007; 56: 137-41.
9. Marckmann P, Skov L, Rossen K et al. Nephroge-nic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced mag-netic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-62.
10. Swaminathan S, Leung N. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006; 145: 234-5.
11. Collidge TA, Thomson PC, Mark PB et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007; 245: 168-75.
12. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Derma-tol 2007; 56: 710-2.
13. Sadowski EA, Bennet LK, Chan MR et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-57.
14. Kanal E, Barkovich AJ, Bell C et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007; 188: 1447-74.
15. Schmook T, Budde K, Ulrich C et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 2005; 20: 220-2.
16. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007; 18: 2636-43.
17. Buajordet I, Madsen S. Alvorlige bivirkninger av Omniscan og Magnevist hos pasienter med nyresvikt. Oslo: Statens legemiddelverk, 2008.